Damora Therapeutics (DMRA) Long-Term Deferred Tax (2023 - 2024)
Damora Therapeutics posted quarterly Long-Term Deferred Tax of $67.2 million for Q4 2024, up 6.02% year-on-year from $63.4 million in Q1 2024, and up 6.02% on a QoQ basis from $63.4 million in Q4 2023.
Damora Therapeutics (DMRA) has 2 years of Long-Term Deferred Tax data on file, last reported at $67.2 million in Q4 2024.
- For the quarter ending Q4 2024, Long-Term Deferred Tax rose 6.02% year-over-year to $67.2 million; the trailing twelve-month figure through Dec 2024 stood at $67.2 million (up 6.02% YoY), and the FY2024 full-year result was $67.2 million, up 6.02% from the prior year.
- Long-Term Deferred Tax for Q4 2024 stood at $67.2 million, up from $63.4 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $67.2 million in Q4 2024 and bottomed at $63.4 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 67.23 Mn |
| Dec 31, 2023 | 63.41 Mn |